Evidence map›Paper›PMID 37869655›Full record

ArticleFrontiers in microbiology2023

Rapid inactivation and sample preparation for SARS-CoV-2 PCR-based diagnostics using TNA-Cifer Reagent E.

Nina M Pollak, Daniel J Rawle, Kexin Yan, Cameron Buckley, Thuy T Le, Claire Y T Wang, Nicole G Ertl, Karla van Huyssteen, Nicole Crkvencic, Misha Hashmi and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Nina M Pollak *Center for Bioinnovation, University of the Sunshine Coast, Sippy Downs, QLD, Australia.
Daniel J Rawle *Inflammation Biology Group, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Kexin YanInflammation Biology Group, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Cameron BuckleyFaculty of Medicine, UQ Centre for Clinical Research, The University of Queensland, Herston, QLD, Australia.
Thuy T LeInflammation Biology Group, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Claire Y T WangQueensland Paediatric Infectious Diseases Laboratory, Centre for Children's Health Research, Brisbane, QLD, Australia.
Nicole G ErtlFaculty of Medicine, UQ Centre for Clinical Research, The University of Queensland, Herston, QLD, Australia.
Karla van HuyssteenBioCifer Pty Ltd., Auchenflower, QLD, Australia.
Nicole CrkvencicBio Molecular Systems, Potts Point, NSW, Australia.
Misha HashmiBio Molecular Systems, Potts Point, NSW, Australia.
Russell E LyonsBioCifer Pty Ltd., Auchenflower, QLD, Australia.
David M WhileyFaculty of Medicine, UQ Centre for Clinical Research, The University of Queensland, Herston, QLD, Australia.
Andreas SuhrbierInflammation Biology Group, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Joanne MacdonaldCenter for Bioinnovation, University of the Sunshine Coast, Sippy Downs, QLD, Australia.
QIMR Berghofer Medical Research Institute · AUUniversity of Queensland · AUUniversity of the Sunshine Coast · AUAustralian e-Health Research Centre · AUChildren's Medical Research Institute · AUQueensland Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RT-qPCR remains a key diagnostic methodology for COVID-19/SARS-CoV-2. Typically, nasal or saliva swabs from patients are placed in virus transport media (VTM), RNA is extracted at the pathology laboratory, and viral RNA is measured using RT-qPCR. In this study, we describe the use of TNA-Cifer Reagent E in a pre-clinical evaluation study to inactivate SARS-CoV-2 as well as prepare samples for RT-qPCR. Adding 1 part TNA-Cifer Reagent E to 5 parts medium containing SARS-CoV-2 for 10 min at room temperature inactivated the virus and permitted RT-qPCR detection. TNA-Cifer Reagent E was compared with established column-based RNA extraction and purification methodology using a panel of human clinical nasal swab samples (

Indexed as

COVID-19diagnosticsRNA extractionRT-qPCRsafetySARS-CoV-2virus inactivation

Identifiers

PMID37869655
PMCPMC10590215
OpenAlexW4387402713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.